Showing results (231-240 of 2,751) with videos related to

Sort By:
Pageof 276
Neoplasia (New York, N.Y.)|May 3, 2011
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancerFanyan Meng, Haijun Zhang, Gang Liu, et al.
Neoplasia (New York, N.Y.)|March 11, 2011
Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosisGregory A Watson, Sanjay Naran, Xinglu Zhang, et al.
Neoplasia (New York, N.Y.)|March 11, 2011
Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cellsKarin Haim, Polina Weitzenfeld, Tsipi Meshel, et al.
Neoplasia (New York, N.Y.)|March 11, 2011
Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic miceJorge M Blando, Steve Carbajal, Erika Abel, et al.
Neoplasia (New York, N.Y.)|March 16, 2011
Tyr phosphatase-mediated P-ERK inhibition suppresses senescence in EIA + v-raf transformed cells, which, paradoxically, are apoptosis-protected in a MEK-dependent mannerStefania De Vitis, Antonella Sonia Treglia, Luca Ulianich, et al.
Neoplasia (New York, N.Y.)|March 16, 2011
Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancerSun-Jin Kim, Jang Seong Kim, Seung Wook Kim, et al.
Neoplasia (New York, N.Y.)|January 20, 2011
Targeted inhibition of multiple receptor tyrosine kinases in mesotheliomaWen-Bin Ou, Christopher Hubert, Joseph M Corson, et al.
Neoplasia (New York, N.Y.)|January 20, 2011
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamideUrban Emmenegger, Giulio Francia, Annabelle Chow, et al.
Neoplasia (New York, N.Y.)|January 22, 2011
Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agentsSteven C Smith, Dmytro M Havaleshko, Kihyuck Moon, et al.
Neoplasia (New York, N.Y.)|October 8, 2010
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivoShafaat A Rabbani, Bushra Ateeq, Ani Arakelian, et al.
Pageof 276